StockData
MapLight Therapeutics, Inc. logo

MapLight Therapeutics, Inc. (MPLT) stock

MPLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$5.94−0.48 (-7.48%)

Close on Nov 20, 2026Market cap $275.48MP/E –Yield –

MapLight Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

MapLight Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$175.12M. For fiscal 2025 it was -$138.61M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$138.61M–
FY2024Dec 31, 2024-$79.59M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$44.89M–
Q1 FY2026Mar 31, 2026-$51.20M–
Q4 FY2025Dec 31, 2025-$47.21M–
Q3 FY2025Sep 30, 2025-$31.82M–
Q4 FY2024Dec 31, 2024-$21.59M–

More MapLight Therapeutics figures

See a number that looks wrong?